Chemotherapy in non-small cell lung cancer

BMJ 1996; 312 doi: https://doi.org/10.1136/bmj.312.7025.248c (Published 27 January 1996) Cite this as: BMJ 1996;312:248

Large trial will reduce uncertainty

  1. R J Stephens,
  2. M K B Parmar,
  3. R L Souhami,
  4. S Spiro
  1. On behalf of the steering committee of the big lung trial Statistician Statistician MRC Cancer Trials Office, Cambridge CB2 2BW
  2. Professor of clinical oncology Department of Oncology, University College London Medical School, Middlesex Hospital, London W1N 8AA
  3. Clinical director of medicine University College London Hospitals, Middlesex Hospital

    EDITOR,—The recent meta-analysis of the role of chemotherapy in non-small cell lung cancer suggests that treatments containing cisplatin improved survival.1 The effect of chemotherapy seemed to be consistent across all subgroups (stage of disease, age, sex, performance status, and tumour histology). Because of the heterogeneity of the treatments used in …

    View Full Text

    Sign in

    Log in through your institution